Drug Policy Research Center Testimony

2018

• 

  Evolution of the U.S. Overdose Crisis: Understanding China's Role in the Production and Supply of Synthetic Opioids 2018

  Bryce Pardo

  Testimony presented before the House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations on September 6, 2018.

• 

  Should Canada "Start Low and Go Slow" When It Comes to Cannabis Potency? 2018

  Beau Kilmer

  Testimony presented before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada on May 7, 2018.

2017

• 

  Considering Cannabis Legalization in Canada: Prices, Taxes, and International Implications 2017

  Beau Kilmer

  Testimony presented before the House of Commons of Canada Standing Committee on Health on September 14, 2017.

• 

  Funding Considerations in the Fight Against the Opioid Epidemic: What the Science Tells Us 2017

  Rosalie Liccardo Pacula

  Testimony presented before the House Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on April 5, 2017.

• 

  Regulating Medical Marijuana Markets: Insights from Scientific Evaluations of State Experiments 2017

  Rosalie Liccardo Pacula

  Testimony presented before the Florida House of Representatives Health & Human Services Committee, Subcommittee on Health Quality on January 25, 2017.

2016

• 

  Marijuana Legalization, Government Revenues, and Public Budgets: Ten Factors to Consider 2016

  Beau Kilmer

  Testimony presented before the Vermont Senate Committee on Finance on January 19, 2016.

2010

• 

  An Assessment of the Scientific Support Underlying the FY2011 Budget Priorities of the Office of National Drug Control Policy 2010

  Rosalie Liccardo Pacula

  Testimony presented before the House Oversight and Government Reform Committee, Subcommittee on Domestic Policy on April 14, 2010.

• 

  Insights on the Effects of Marijuana Legalization on Prices and Consumption 2010

  Beau Kilmer

  Testimony presented before the California State Assembly Public Safety Committee and California State Senate Public Safety Committee on September 21, 2010.

2009

• 

  Legalizing Marijuana: Issues to Consider Before Reforming California State Law 2009

  Rosalie Liccardo Pacula

  Testimony presented before the California State Assembly Public Safety Committee on October 28, 2009.

2008

• 

  What Research Tells Us About the Reasonableness of the Current Priorities of National Drug Control 2008

  Rosalie Liccardo Pacula

  Testimony presented before the House Oversight and Government Reform Committee, Subcommittee on Domestic Policy on March 12, 2008.

2005

• 

  An Assessment of ONDCP's Budget Concept 2005

  Peter H. Reuter

  Testimony presented to the House of Representatives Committee on Government Reform on February 10, 2005.

2001

• 

  The Costs of Covering Mental Health and Substance Abuse Care at the Same Level as Medical Care in Private Insurance Plans 2001

  Roland Sturm

  Testimony presented to the Health Insurance Committee, National Conference of Insurance Legislators on July 13, 2001.

2000

• 

  Should the U.S. Direct More Law Enforcement Effort at XTC? 2000

  Jonathan P. Caulkins

  Testimony presented to the Subcommittee on Crime of the House Committee on the Judiciary on June 15, 2000.

• 

  Testimony on Drug Treatment Alternatives to Incarceration 2000

  Martin Y. Iguchi

  Testimony presented to the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the House Committee on Government Reform, April 4, 2000.

• 

  What is SAMHSA Doing to Help Communities Make Good Decisions About the Allocation of Scarce Treatment Resources? 2000

  Martin Y. Iguchi

  Testimony presented to the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the House Committee on Government Reform, February 17, 2000.

1999

• 

  Comparing the Cost-Effectiveness of Federal Mandatory Minimum Sentences and Other Federal Enforcement Programs 1999

  Peter H. Reuter, Susan S. Sohler Everingham

  Testimony presented to the Subcommittee on Crime of the House Committee on the Judiciary on July 29, 1999.

• 

  Effects of Substance Abuse Parity in Private Insurance Plans Under Managed Care 1999

  Roland Sturm

  Testimony presented Submitted to the U.S. House of Representatives Subcommittee on Criminal Justice, Drug Policy and Human Resources on October 21, 1999.

• 

  What We Do and Don’t Know About the Likely Effects of Decriminalization and Legalization: A Brief Summary 1999

  Robert J. MacCoun, Peter H. Reuter

  Testimony before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the House Committee on Government Reform Tuesday, on July 13, 1999.